Edition:
United Kingdom

Agios Pharmaceuticals Inc (AGIO.OQ)

AGIO.OQ on NASDAQ Stock Exchange Global Select Market

52.96USD
8:04pm GMT
Change (% chg)

$-2.04 (-3.71%)
Prev Close
$55.00
Open
$55.11
Day's High
$55.11
Day's Low
$52.50
Volume
92,689
Avg. Vol
143,462
52-wk High
$72.66
52-wk Low
$39.25

Chart for

About

Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company's cancer product candidates are... (more)

Overall

Beta: 1.94
Market Cap(Mil.): $3,409.16
Shares Outstanding(Mil.): 48.39
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Agios Pharmaceuticals Presents New Safety Data From Study on Leukemia Drug

* PRESENTS NEW SAFETY DATA FROM PHASE 1 EXPANSION STUDY EVALUATING ORAL IVOSIDENIB IN PATIENTS WITH R/R AML AND IDH1 MUTATION

11 Dec 2017

Promising responses seen with Agios leukemia drug in study

Nearly a third of patients with an advanced form of a fast-progressing leukemia who carry a specific genetic mutation experienced a complete or near complete response to an experimental Agios Pharmaceuticals drug, according to data from an early stage trial released on Monday.

11 Dec 2017

Promising responses seen with Agios leukemia drug in study

Dec 11 Nearly a third of patients with an advanced form of a fast-progressing leukemia who carry a specific genetic mutation experienced a complete or near complete response to an experimental Agios Pharmaceuticals drug, according to data from an early stage trial released on Monday.

11 Dec 2017

BRIEF-Agios Pharmaceuticals Files For Potential Mixed Shelf Offering

* AGIOS PHARMACEUTICALS INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING Source text: (http://bit.ly/2yOMDeC) Further company coverage:

08 Dec 2017

BRIEF-Agios presents updated phase 1 data from dose expansion cohort of ivosidenib

* Agios presents updated phase 1 data from dose expansion cohort of ivosidenib (AG-120) in patients with IDH1 mutant positive glioma

17 Nov 2017

BRIEF-Agios reports Q3 revenue $11.4 million

* Agios Pharmaceuticals Inc - Qtrly ‍net loss per share $1.59 Source text for Eikon: Further company coverage:

01 Nov 2017

BRIEF-Agios posts Q2 loss per share $1.78‍​

* Agios Pharmaceuticals Inc - ‍collaboration revenue was $11.3 million for quarter ended June 30, 2017, compared to $7.0 million for comparable period in 2016​

08 Aug 2017

FDA approves leukemia treatment developed by Celgene, Agios

The U.S. Food and Drug Administration (FDA) on Tuesday approved Celgene Corp and Agios Pharmaceuticals Inc's oral treatment for acute myeloid leukemia (AML) patients with a rare genetic mutation.

01 Aug 2017

UPDATE 2-FDA approves leukemia treatment developed by Celgene, Agios

* Oppenheimer estimates Idhifa sales of $1.4 bln in 2021 (Adds pricing details, analyst comments and share move)

01 Aug 2017

BRIEF-Agios Pharma says FDA approves Idhifa for treating relapsed/refractory Acute Myeloid Leukemia

* FDA grants approval of Idhifa, the first oral targeted therapy for adult patients with relapsed/refractory acute myeloid leukemia and an IDH2 mutation Source text for Eikon: Further company coverage:

01 Aug 2017

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $36.46 -0.18
Novartis AG (NOVN.S) CHF83.85 0.00
Roche Holding Ltd. (ROG.S) CHF241.70 0.00
Roche Holding Ltd. (RO.S) CHF242.50 -0.70
Sanofi SA (SASY.PA) €73.77 -0.89
AstraZeneca plc (AZN.L) 4,884.50 -40.50
GlaxoSmithKline plc (GSK.L) 1,290.50 -23.50
Eli Lilly and Co (LLY.N) $86.50 -1.39
Shire PLC (SHP.L) 3,685.00 +7.50
Shire PLC (3159084.L) -- --

Earnings vs. Estimates